Researcher working with laboratory equipment

CasInvent Pharma

Pipeline

Advancing selective CK1 inhibitors.

Explore

Pipeline
priorities	indication	hit discovery	investigational new drug application	clinical trials Phase Ia/Ib	exit
1stliquid tumors	AML/CLL (CI2420B)	in vivo PoC	2026/27	2027	2029
2ndsolid tumors	PDAC	in vivo PoC	2026/27
3rdsolid tumors	Prostate, Melanoma (CI2420B)		TBA
4ndsolid tumors	CRC (TBD)		TBA
5rdCNS	Huntington, ALS, PD etc (CI1998)	to be partnered with CNS companies (first collaboration started)

1st liquid tumors

AML/CLL (CI2420B)

in vivo PoC

investigational new drug application: 2026/27
clinical trials Phase Ia/Ib: 2027

2nd solid tumors

PDAC

in vivo PoC

investigational new drug application: 2026/27

3rd solid tumors

Prostate, Melanoma (CI2420B)

investigational new drug application: TBA

4nd solid tumors

CRC (TBD)

investigational new drug application: TBA

5rd CNS

Huntington, ALS, PD etc (CI1998)

to be partnered with CNS companies (first collaboration started)

exit 2029

View original ↗

CasInvent Pharma is developing selective small molecule inhibitors of casein kinase 1(CK1). Other indications in the field of oncology are being studied, using the lead candidate as well as other molecules in our portfolio. CasInvent intends to advance its lead candidates to the clinical phase Ib.

The IP is subject to the exclusive sublicenceable worldwide license from the Masaryk University.

Our Science

Our Publications